<DOC>
	<DOCNO>NCT01902771</DOCNO>
	<brief_summary>DC vaccine manufacture partially mature use standard operating procedure , develop collaboration HGG Immuno Group , administer imiquimod treat skin safe feasible child refractory brain tumor . This result anti-tumor immunity prolong survival subject treat result consistent outcomes found subject treat HGG Immuno Group investigator . Study treatment correlate laboratory evidence immune activation . Correlative study also reveal target immune system exploit improve response patient successor trial .</brief_summary>
	<brief_title>Dendritic Cell Vaccine Therapy With In Situ Maturation Pediatric Brain Tumors</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>1 . Age : ≥ 1 year ≤ 29 year 2 . Relapse progression central nervous system tumor initially diagnose age 21 year . 3 . Total subtotal resection tumor mass , confirm assessment neurosurgeon postoperative MRI scan within 72 hour surgery . The postoperative assessment demonstrate residual tumor less equal 2 cm^3 judge surgeon MRI tumor show linear contrast enhancement border resection cavity nodule le 2 cm^3 . 4 . No radiotherapy and/or chemotherapy receive least 1 month first DC vaccination administer . 5 . No treatment corticosteroid salicylates least 1 week first vaccination . 6 . Life expectancy ≥ 3 month 7 . Written consent patient parent ( ) ( patient &lt; 18 year ) institutional review board ( IRB ) approve informed consent form prior studyspecific evaluation . Assent required child per University Miami ( UM ) IRB guideline . Subject must capable understanding investigational nature , potential risk benefit study able provide valid inform consent . 8 . Adequate organ function ( measure enrollment ) Absolute neutrophil count ( ANC ) ≥750/L Lymphocytes ≥ 500/L Platelets ≥ 75,000/L Hemoglobin ≥ 9 g/dL Aspartate aminotransferase ( AST ) /Alanine transaminase ( ALT ) ≤ 2.5 X upper limit normal ( ULN ) ; liver metastasis , ≤ 5 X ULN Serum Creatinine ≤ 1.5 X ULN Total Bilirubin ≤ 3 X ULN Albumin &gt; 2 g/dL 9 . Subjects must agree use adequate method contraception abstinence throughout 4 week study treatment completion . 10 . Karnofsky score ≥ 70 Eastern Cooperative Oncology Group ( ECOG ) status 0 1 . 1 . Pregnancy . 2 . Breast feeding female . 3 . Any concomitant participation therapeutic trial . 4 . Virus serology positive HIV ( test require absence clinical suspicion ) . 5 . Documented immunodeficiency autoimmune disease . 6 . Other active malignancy . 7 . Refusal use adequate contraception fertile patient ( female male ) study 30 day last dose study treatment . 8 . Any serious uncontrolled medical psychiatric condition opinion investigator make patient able participate study . 9 . Application gliadel wafer within prior 4 month plan place Gliadel wafer time resection tumor acquisition study .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dendritic Cell Vaccine</keyword>
	<keyword>DCV</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>In Situ</keyword>
	<keyword>Lysate</keyword>
	<keyword>Tumor Lysate</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>GBM</keyword>
	<keyword>Pheresis</keyword>
	<keyword>Leukapheresis</keyword>
	<keyword>High Grade Glioma</keyword>
	<keyword>HGG</keyword>
</DOC>